Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2018
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2018
SUMMARY
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Telomerase Reverse Transcriptase - Pipeline Review, H2 2018, outlays comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 2, 10 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Male Health, Respiratory, Hematological Disorders and Women's Health which include indications Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Gastric Cancer, Ovarian Cancer, Aplastic Anemia, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Idiopathic Pulmonary Fibrosis, Lung Adenocarcinoma, Lymphoma, Male Infertility, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Pulmonary Fibrosis, Renal Cell Carcinoma, Sarcomas, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Women Infertility.
Furthermore, this report also reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Telomerase Reverse Transcriptase - Pipeline Review, H2 2018, outlays comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 2, 10 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Male Health, Respiratory, Hematological Disorders and Women's Health which include indications Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Gastric Cancer, Ovarian Cancer, Aplastic Anemia, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Idiopathic Pulmonary Fibrosis, Lung Adenocarcinoma, Lymphoma, Male Infertility, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Pulmonary Fibrosis, Renal Cell Carcinoma, Sarcomas, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Women Infertility.
Furthermore, this report also reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
- The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects
- The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development
Asterias Biotherapeutics Inc
e-Therapeutics Plc
F. Hoffmann-La Roche Ltd
GemVax & KAEL Co Ltd
Geron Corp
Inovio Pharmaceuticals Inc
Invectys SA
Komipharm International Co Ltd
Mediolanum farmaceutici SpA
Takis Srl
Telocyte LLC
TILT Biotherapeutics Ltd
Ultimovacs AS
Vaxon Biotech
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles
Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTVAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTVAC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETS-2300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate TERT for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imetelstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INVAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KML-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ribovax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Telomerase for Men Infertility and Women Infertility - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Telomerase for Lung Cancer and Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TERT for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Telomerase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEL-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TILT-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TK-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCPVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vx-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vx-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Products
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Product Development Milestones
Featured News & Press Releases
Sep 04, 2018: Asterias Biotherapeutics announces positive outcome from Second Safety Review Committee Meeting and open enrollment for VAC2 clinical trial in non-small cell lung cancer (NSCLC)
Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab
Jul 11, 2018: Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
Jun 28, 2018: Southampton vaccinate first patient to phase 1 study
Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor
Jun 18, 2018: Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress
Jun 12, 2018: Cancer Research Uk Tests First Of Its Kind Vaccine To Treat Lung Cancer
May 17, 2018: Geron Announces Oral Presentation at European Hematology Association Congress
May 16, 2018: Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress
Apr 25, 2018: Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2
Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia
Mar 24, 2018: New Preclinical Data for THIO in BRAF-Mutant Mouse Melanoma Models
Jan 30, 2018: CNIO researchers cure lung fibrosis in mice with a gene therapy that lengthens telomeres
Jan 04, 2018: Asterias Biotherapeutics Provides Update on ASTVAC-2
Dec 19, 2017: PharmaJet and Invectys Partner in Phase II Clinical Trial of DNA Cancer Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development
Asterias Biotherapeutics Inc
e-Therapeutics Plc
F. Hoffmann-La Roche Ltd
GemVax & KAEL Co Ltd
Geron Corp
Inovio Pharmaceuticals Inc
Invectys SA
Komipharm International Co Ltd
Mediolanum farmaceutici SpA
Takis Srl
Telocyte LLC
TILT Biotherapeutics Ltd
Ultimovacs AS
Vaxon Biotech
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles
Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTVAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTVAC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETS-2300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate TERT for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imetelstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INVAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KML-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ribovax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Telomerase for Men Infertility and Women Infertility - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Telomerase for Lung Cancer and Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TERT for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Telomerase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEL-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TILT-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TK-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCPVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vx-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vx-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Products
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Product Development Milestones
Featured News & Press Releases
Sep 04, 2018: Asterias Biotherapeutics announces positive outcome from Second Safety Review Committee Meeting and open enrollment for VAC2 clinical trial in non-small cell lung cancer (NSCLC)
Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab
Jul 11, 2018: Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
Jun 28, 2018: Southampton vaccinate first patient to phase 1 study
Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor
Jun 18, 2018: Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress
Jun 12, 2018: Cancer Research Uk Tests First Of Its Kind Vaccine To Treat Lung Cancer
May 17, 2018: Geron Announces Oral Presentation at European Hematology Association Congress
May 16, 2018: Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress
Apr 25, 2018: Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2
Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia
Mar 24, 2018: New Preclinical Data for THIO in BRAF-Mutant Mouse Melanoma Models
Jan 30, 2018: CNIO researchers cure lung fibrosis in mice with a gene therapy that lengthens telomeres
Jan 04, 2018: Asterias Biotherapeutics Provides Update on ASTVAC-2
Dec 19, 2017: PharmaJet and Invectys Partner in Phase II Clinical Trial of DNA Cancer Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Asterias Biotherapeutics Inc, H2 2018
Pipeline by e-Therapeutics Plc, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by GemVax & KAEL Co Ltd, H2 2018
Pipeline by Geron Corp, H2 2018
Pipeline by Inovio Pharmaceuticals Inc, H2 2018
Pipeline by Invectys SA, H2 2018
Pipeline by Komipharm International Co Ltd, H2 2018
Pipeline by Mediolanum farmaceutici SpA, H2 2018
Pipeline by Takis Srl, H2 2018
Pipeline by Telocyte LLC, H2 2018
Pipeline by TILT Biotherapeutics Ltd, H2 2018
Pipeline by Ultimovacs AS, H2 2018
Pipeline by Vaxon Biotech, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Asterias Biotherapeutics Inc, H2 2018
Pipeline by e-Therapeutics Plc, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by GemVax & KAEL Co Ltd, H2 2018
Pipeline by Geron Corp, H2 2018
Pipeline by Inovio Pharmaceuticals Inc, H2 2018
Pipeline by Invectys SA, H2 2018
Pipeline by Komipharm International Co Ltd, H2 2018
Pipeline by Mediolanum farmaceutici SpA, H2 2018
Pipeline by Takis Srl, H2 2018
Pipeline by Telocyte LLC, H2 2018
Pipeline by TILT Biotherapeutics Ltd, H2 2018
Pipeline by Ultimovacs AS, H2 2018
Pipeline by Vaxon Biotech, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd.1), H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Asterias Biotherapeutics Inc
e-Therapeutics Plc
F. Hoffmann-La Roche Ltd
GemVax & KAEL Co Ltd
Geron Corp
Inovio Pharmaceuticals Inc
Invectys SA
Komipharm International Co Ltd
Mediolanum farmaceutici SpA
Takis Srl
Telocyte LLC
TILT Biotherapeutics Ltd
Ultimovacs AS
Vaxon Biotech
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Asterias Biotherapeutics Inc
e-Therapeutics Plc
F. Hoffmann-La Roche Ltd
GemVax & KAEL Co Ltd
Geron Corp
Inovio Pharmaceuticals Inc
Invectys SA
Komipharm International Co Ltd
Mediolanum farmaceutici SpA
Takis Srl
Telocyte LLC
TILT Biotherapeutics Ltd
Ultimovacs AS
Vaxon Biotech
